The fund would not replace existing patent laws, but would offer an alternative to them. Pharmaceutical companies could continue to patent and sell their products as they do now.  Alternatively, they could register a new drug with the Heath Impact Fund, which would set a low price based on the drug’s manufacturing cost.
药厂有资格在接下来的十年中，从基金获得一部分款项，而不是靠高价出售药品盈利。至于获得的数额，会通过评估该药对降低死亡和残疾的贡献来计算。